SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+12.51%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.47B
AUM Growth
+$1.47B
(+11%)
Cap. Flow
+$119K
Cap. Flow
% of AUM
0.01%
Top 10 Holdings %
Top 10 Hldgs %
55.99%
Holding
73
New
9
Increased
18
Reduced
19
Closed
13
Top Buys
| 1 |
Gilead Sciences
GILD
|
$70M |
| 2 |
AbbVie
ABBV
|
$49.3M |
| 3 |
Boston Scientific
BSX
|
$46.3M |
| 4 |
Eli Lilly
LLY
|
$34.5M |
| 5 |
United Therapeutics
UTHR
|
$34.1M |
Top Sells
| 1 |
Stryker
SYK
|
$111M |
| 2 |
Medtronic
MDT
|
$50.6M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$47.6M |
| 4 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$36.5M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$23.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Natera
NTRA
$23.1B
| $262M | 16.02% | 1,550,280 | – | – |
|
|
2
Gilead Sciences
GILD
$140B
| $116M | 7.12% | 1,050,308 +631,408 | +151% | +$70M |
|
|
3
Eli Lilly
LLY
$657B
| $75.6M | 4.63% | 97,018 +44,218 | +84% | +$34.5M |
|
4
Jazz Pharmaceuticals
JAZZ
$7.75B
| $73.7M | 4.51% | 694,096 +184,046 | +36% | +$19.5M |
|
5
Vera Therapeutics
VERA
$1.38B
| $65.8M | 4.03% | 2,793,987 | – | – |
|
|
6
AbbVie
ABBV
$372B
| $49.3M | 3.02% | +265,850 | New | +$49.3M |
|
|
7
Boston Scientific
BSX
$156B
| $46.3M | 2.83% | +431,200 | New | +$46.3M |
|
8
DexCom
DXCM
$29.5B
| $45.7M | 2.8% | 523,694 +127,719 | +32% | +$11.1M |
|
9
IDEAYA Biosciences
IDYA
$2.15B
| $45.1M | 2.76% | 2,147,795 -474,397 | -18% | -$9.97M |
|
10
BridgeBio Pharma
BBIO
$9.89B
| $42.9M | 2.62% | 993,093 +258,866 | +35% | +$11.2M |
|
11
Intuitive Surgical
ISRG
$170B
| $38.4M | 2.35% | 70,642 +58,658 | +489% | +$31.9M |
|
12
Rhythm Pharmaceuticals
RYTM
$6.85B
| $37M | 2.26% | 586,010 +139,171 | +31% | +$8.79M |
|
13
ArriVent BioPharma
AVBP
$776M
| $36.9M | 2.26% | 1,696,752 | – | – |
|
14
Roivant Sciences
ROIV
$8.15B
| $34.8M | 2.13% | 3,088,814 +1,809,304 | +141% | +$20.4M |
|
15
Soleno Therapeutics
SLNO
$3.6B
| $34.8M | 2.13% | 415,219 -69,252 | -14% | -$5.8M |
|
|
16
United Therapeutics
UTHR
$13.8B
| $34.1M | 2.08% | +118,513 | New | +$34.1M |
|
17
Insmed
INSM
$28.8B
| $31.6M | 1.93% | 313,923 +9,669 | +3% | +$973K |
|
18
Akero Therapeutics
AKRO
$3.74B
| $29.3M | 1.79% | 548,788 +38,768 | +8% | +$2.07M |
|
19
Supernus Pharmaceuticals
SUPN
$2.53B
| $25.2M | 1.54% | 799,253 +278,575 | +54% | +$8.78M |
|
20
AnaptysBio
ANAB
$569M
| $22.9M | 1.4% | 1,032,362 -127,671 | -11% | -$2.83M |
|
|
RAPP
21
Rapport Therapeutics
RAPP
$643M
| $22.7M | 1.39% | 1,995,594 | – | – |
|
22
uniQure
QURE
$896M
| $21.7M | 1.33% | 1,558,356 +1,012,585 | +186% | +$14.1M |
|
23
Merus
MRUS
$4.98B
| $21.3M | 1.3% | +404,562 | New | +$21.3M |
|
24
AstraZeneca
AZN
$248B
| $20.5M | 1.26% | +293,661 | New | +$20.5M |
|
25
PTC Therapeutics
PTCT
$3.92B
| $18.4M | 1.12% | 375,939 -203,400 | -35% | -$9.93M |
|